Gilead Sciences Stock Plummets 2.58% Amid FDA Clinical Trial Halt, Trading Volume Surges to 77th Rank

On June 10, 2025, Gilead Sciences (GILD) experienced a significant decline in its stock price, dropping by 2.58%. The trading volume for the day was substantial, reaching $9.83 billion, marking a 41.59% increase from the previous day. This placed Gilead among the top 77 most actively traded stocks for the day.

The decline in Gilead's stock price was primarily driven by the U.S. Food and Drug Administration's (FDA) decision to halt clinical trials for two of the company's investigational HIV drugs. The FDA's action was prompted by safety concerns, specifically a decrease in CD4+ T-cell counts and absolute lymphocyte counts in some participants. This clinical hold affected the trials of GS-1720 and GS-4182, which were being tested as a two-drug combination to treat HIV.

GS-4182 is a pill version of Gilead's existing HIV treatment, lenacapavir, while GS-1720 is a weekly administered drug in development. The FDA's intervention has raised questions about the safety and efficacy of these investigational treatments, leading to investor caution and a subsequent drop in the stock price.

Despite this setback, Gilead has a robust pipeline with 58 investigational programs, indicating that the company is actively developing next-generation HIV treatments. The clinical hold on the two drugs is seen as a temporary obstacle rather than a major setback, given the company's diverse portfolio of HIV combination treatments.